Another study, by Zamora Atenza and colleagues, in 119 patients with advanced NSCLC treated with anti-PD-(L)1, sought to integrate PD-L1 expression on various immune subsets in peripheral blood, including monocytes and platelets, as predictive biomarkers of response [95]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.